Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), and its pathogenesis is not fully understood. Previously, we showed that fractalkine (FKN) expression was positively correlated with the severity of LN. Here, we aimed to study the role of the Hippo signaling pathway (HSP) and its interaction with FKN in LN in an attempt to provide novel strategies for LN treatment.
Methods
In this study, lipopolysaccharide (LPS)/interferon-γ (IFN-γ)-stimulated THP-1 cells were co-cultured with FKN up-regulated or down-regulated kidney epithelial cells Hkb20. FKN-knockout (KO-FKN) mice were used to construct LN model. Flow cytometric analysis, quantitative real-time polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), pathological staining, Western blot, and immunofluorescence (IF) staining were employed to investigate the role of FKN and its interaction with the Hippo signaling pathway (HSP) in LN.
Results
Up-regulation of FKN in kidney epithelial cells was associated with increased macrophage activation. FKN overexpression in kidney epithelial cells suppressed apoptosis, inflammation levels, and M1 polarization of THP-1 cells and inhibited the HSP. Oppositely, FKN knockdown in kidney epithelial cells increased apoptosis, inflammation, and M1 polarization and activated the HSP. HSP inhibitor reversed the effect of FKN knockdown on THP-1 cells. In LN mice, FKN knockout and YAP inhibitor decreased the levels of renal function markers, alleviated kidney injury induced by LN, and inhibited macrophage activation in LN mice.
Conclusions
FKN down-regulation reduced the activation of macrophages in renal tissue and alleviated kidney damage by activating HSP. The regulatory effect of FKN on HSP should be confirmed in patients with LN, and the mechanism of FKN in LN should be further explored.
StojanGPetriM. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol2018; 30: 144–150.
2.
AndersHJSaxenaRZhaoMH, et al.Lupus nephritis. Nat Rev Dis Primers2020; 6: 7.
3.
KiriakidouMChingCL. Systemic lupus erythematosus. Ann Internal Med2020; 172: Itc81–itc96.
4.
Bashford-RogersRJMBergamaschiLMcKinneyEF, et al.Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature2019; 574: 122–126.
5.
WangLLawHK. Immune complexes impaired glomerular endothelial cell functions in lupus nephritis. Int J Mol Sci2019; 20: 5281.
6.
WatanabeSAlexanderMMisharinAV, et al.The role of macrophages in the resolution of inflammation. J Clin Investig2019; 129: 2619–2628.
7.
ChenSYangJWeiY, et al.Epigenetic regulation of macrophages: from homeostasis maintenance to host defense. Cell Mol Immunol2020; 17: 36–49.
8.
HuLHuJChenL, et al.Interleukin-22 from type 3 innate lymphoid cells aggravates lupus nephritis by promoting macrophage infiltration in lupus-prone mice. Front Immunol2021; 12: 584414.
9.
JuliaVStaumont-SalleDDombrowiczD. Rôle de la fractalkine/CX3CL1 et de son récepteur CX3CR1 dans les pathologies allergiques. Med Sci2016; 32: 260–266.
10.
FuruichiKGaoJLMurphyPM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol2006; 169: 372–387.
11.
ChanHCChanHCLiangCJ, et al.Role of low-density lipoprotein in early vascular aging associated with systemic lupus erythematosus. Arthritis Rheumatol2020; 72: 972–984.
12.
BazanJFBaconKBHardimanG, et al.A new class of membrane-bound chemokine with a CX3C motif. Nature1997; 385: 640–644.
13.
CormicanSGriffinMD. Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease?Front Immunol2021; 12: 664202.
14.
YouYQinYLinX, et al.Upregulated fractalkine levels in Chinese patients with lupus nephritis. Cytokine2018; 104: 23–28.
15.
FuDSenouthaiSWangJ, et al.FKN facilitates HK-2 cell EMT and tubulointerstitial lesions via the Wnt/β-catenin pathway in a murine model of lupus nephritis. Front Immunol2019; 10: 784.
16.
SharifAADHergovichA. The NDR/LATS protein kinases in immunology and cancer biology. Semin Cancer Biol2018; 48: 104–114.
17.
BaeSJLuoX. Activation mechanisms of the Hippo kinase signaling cascade. Biosci Rep2018; 38: BSR20171469.
MazzoneRZwergelCArticoM, et al.The emerging role of epigenetics in human autoimmune disorders. Clin Epigenet2019; 11: 34.
20.
MorariJAnheGFNascimentoLF, et al.Fractalkine (CX3CL1) is involved in the early activation of hypothalamic inflammation in experimental obesity. Diabetes2014; 63: 3770–3784.
21.
GongQJiangYPanX, et al.Fractalkine aggravates LPS-induced macrophage activation and acute kidney injury via Wnt/β-catenin signalling pathway. J Cell Mol Med2021; 25: 6963–6965.
22.
QiuXLiangTWuZ, et al.Melatonin reverses tumor necrosis factor-alpha-induced metabolic disturbance of human nucleus pulposus cells via MTNR1B/Gαi2/YAP signaling. Int J Biol Sci2022; 18: 2202–2219.
23.
SatohMRichardsHBShaheenVM, et al.Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol2000; 121: 399–405.
24.
ReevesWHLeePYWeinsteinJS, et al.Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol2009; 30: 455–464.
25.
GunawanMHerZLiuM, et al.A novel human systemic lupus erythematosus model in humanised mice. Sci Rep2017; 7: 16642.
26.
FanFHeZKongLL, et al.Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med2016; 8: 352ra108.
27.
LuXYuHMaJ, et al.Loss of Mst1/2 activity promotes non-mitotic hair cell generation in the neonatal organ of Corti. NPJ Regen Med2022; 7: 64.
28.
WuQMiaoXZhangJ, et al.Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-β signaling. Theranostics2021; 11: 8480–8499.
29.
ZhangKLiJShiZ, et al.Ginsenosides regulates innate immunity to affect immune microenvironment of AIH through hippo-YAP/TAZ signaling pathway. Front Immunol2022; 13: 851560.
30.
CockwellPChakravortySJGirdlestoneJ, et al.Fractalkine expression in human renal inflammation. J Pathol2002; 196: 85–90.
31.
ZengYLinQYuL, et al.Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus. BMC Immunol2021; 22: 82.
JonesBKochAEAhmedS. Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions. Front Immunol2011; 2: 82.
34.
LiFZhangHXuKY, et al.Role of the chemokine fractalkine in a rat model of acute necrotizing pancreatitis and the interventional effect of ulinastatin. Arch Iran Med2013; 16: 83–87.
35.
ChuLLiXYuW, et al.Expression of fractalkine (CX3CL1) and its receptor in endotoxin-induced uveitis. Ophthalmic Res2009; 42: 160–166.
36.
FuDMaJGongQ, et al.Fractalkine mediates lymphocyte inflammation and tubulointerstitial lesions by modifying the Treg/Th17 balance in lupus-prone MRL/lpr mice. Am J Transl Res2020; 12: 6170–6186.
37.
InoueAHasegawaHKohnoM, et al.Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum2005; 52: 1522–1533.
38.
GordonSPlüddemannA. Macrophage clearance of apoptotic cells: a critical assessment. Front Immunol2018; 9: 127.
39.
WangYSmithWHaoD, et al.M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharm2019; 70: 459–466.
40.
HoruluogluBBayikDKayrakliogluN, et al.PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun2019; 99: 24–32.
41.
LiangCLJiangHFengW, et al.Total glucosides of paeony ameliorate pristane-induced lupus nephritis by inducing PD-1 ligands(+) macrophages via activating IL-4/STAT6/PD-L2 signaling. Front Immunol2021; 12: 683249.
42.
SunWYanSYangC, et al.Mesenchymal stem cells-derived exosomes ameliorate lupus by inducing M2 macrophage polarization and regulatory T Cell expansion in MRL/lpr mice. Immunol Invest2022; 51: 1785–1803.
43.
LeeSHuenSNishioH, et al.Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol2011; 22: 317–326.
44.
Carvalho-PintoCEGarcíaMIMelladoM, et al.Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol2002; 169: 1058–1067.
45.
KulkarniOPawarRDPurschkeW, et al.Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol2007; 18: 2350–2358.
46.
ChalmersSAChituVRamanujamM, et al.Therapeutic targeting of macrophages in lupus nephritis. Discov Med2015; 20: 43–49.
47.
TianSZhangLTangJ, et al.HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. Am J Physiol Ren Physiol2015; 308: F69–F75.
48.
MaRJiangWLiZ, et al.Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. Lupus2016; 25: 1577–1586.
49.
MaSMengZChenR, et al.The hippo pathway: biology and pathophysiology. Annu Rev Biochem2019; 88: 577–604.
50.
SongJWangTChiX, et al.Kindlin-2 inhibits the hippo signaling pathway by promoting degradation of MOB1. Cell Rep2019; 29: 3664–3677. e5.
51.
FengJLiHZhangY, et al.Mammalian STE20-like kinase 1 deletion alleviates renal ischaemia-reperfusion injury via modulating mitophagy and the AMPK-YAP signalling pathway. Cell Physiol Biochem2018; 51: 2359–2376.
52.
XuJLiPXWuJ, et al.Involvement of the Hippo pathway in regeneration and fibrogenesis after ischaemic acute kidney injury: YAP is the key effector. Clin Sci2016; 130: 349–363.
53.
XiaoHZhangQNSunQX, et al.Transcriptomic analysis reveals a link between hippo signaling pathway and macrophages in lungs of mice with OVA-induced allergic asthma. J Inflamm Res2022; 15: 423–437.
54.
XuDChenP-QZhengP-Q, et al.KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury. Acta Pharmacol Sin2021; 42: 436–450.
